久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Inventory of New Drug Targets in 2023 roger
    May 21, 2024
    In 2023, 49 new drugs received their first approval in the United States, the European Union, and Japan.
  • Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
    August 08, 2019
    Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY? clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.
  • Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
    August 08, 2019
    Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY? clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.
PharmaSources Customer Service